The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

Bagsværd, Denmark, 4 February 2026 - Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: ...

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

Ambassador Jesper Møller Sørensen emphasized decades of scientific and industrial links between Boston and Denmark as he ...

The selloff comes as Wall Street is reassessing long-held expectations that the obesity drug market could hit $150 billion early next decade, as U.S. prices for GLP-1 treatments from Novo and Lilly ...

COPENHAGEN, Feb 3 () - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% this year ...

Governor Maura Healey and Denmark’s Ambassador to the U.S., Jesper Møller Sørensen, signed an economic partnership agreement ...

COPENHAGEN, Feb 3 () - ​Wegovy ‌maker Novo ‌Nordisk expects a decline ⁠in ‌sales this year, ‍it said on ​Tuesday ‌as it reported fourth-quarter operating profit ⁠slightly above ​forecasts. (Reporting ...

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.